IDeate-Lung02: a Phase 3 study of second-line ifinatamab deruxtecan in patients with relapsed small cell lung cancer.
Taofeek K Owonikoko, Lauren Byers, Ying Cheng...
https://pubmed.ncbi.nlm.nih.gov/41055143/Actively Recruiting
Led by Daiichi Sankyo · Updated on 2026-08-06
540
Participants Needed
229
Research Sites
95 weeks
Total Duration
Researchers are evaluating the effectiveness and safety of Ifinatamab Deruxtecan I-DXd compared to the treatment chosen by a physician for people with relapsed small cell lung cancer SCLC. This Phase 3 study aims to see if I-DXd can help participants live longer than current treatments, while also examining other effects such as patient-reported outcomes, immune response, and the drugs behavior in the body. Participants will be randomly assigned to one of two groups. One group will receive I-DXd as an intravenous infusion at a dose of 12 mgkg every 21 days until the disease worsens, unacceptable side effects occur, or other stopping reasons arise. The other group will receive one of the standard treatments chosen by their doctortopotecan, lurbinectedin, or amrubicinaccording to local approved dosing guidelines and until treatment discontinuation criteria are met. During the study, participants will be closely monitored with regular imaging and assessments to track tumor response, disease progression, and quality of life using questionnaires. Safety events and immune responses will also be recorded. Pharmacokinetic samples will be collected at specified times to understand how I-DXd behaves in the body. Participants may remain in the study for up to approximately 3.7 years, allowing for long-term evaluation of outcomes and safety.
CONDITIONS
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
D
Daiichi Sankyo Contact for Clinical Trial Information
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Daiichi Sankyo
Lead Sponsor
Merck Sharp & Dohme LLC
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | I‑DXd (12 mg/kg Q3W) | Physician‑chosen standard chemotherapy | Standard second‑line chemotherapy |
|---|---|---|---|
| What it is | A B7‑H3‑directed antibody‑drug conjugate (ADC) delivered at 12 mg/kg intravenously every 3 weeks | Patient receives single‑agent chemotherapy chosen by their physician (such as topotecan, amrubinectin, or lurbinectedin) | Usual second‑line care consists of single‑agent chemotherapy such as topotecan or lurbinectedin, depending on prior platinum‑free interval and patient status |
| Role in trial | Investigational study drug arm | Active comparator arm using physician‑selected standard chemotherapy | Represents usual care outside the trial at this disease stage |
| Primary use | Novel B7‑H3‑targeted ADC for relapsed ES‑SCLC | Standard approved chemotherapy agents for second‑line treatment | Second‑line single‑agent chemotherapy remains the usual treatment approach for relapsed ES‑SCLC |
| How it is given or performed | Administered intravenously every 3 weeks at a fixed antibody‑drug conjugate dose of 12 mg/kg | Administered as per local standard practice for chosen single‑agent chemotherapy | Given per established dosing schedules for each agent in clinical practice |
| Evidence status | Phase II trial showed ~48% response rate, median duration of response 5.3 months, PFS ~4.9 months, and 9‑month survival ~59% | Comparative efficacy varies by agent; topotecan and lurbinectedin historically offer modest response rates | Historically limited efficacy; no new standard established beyond single agents |
| Important risks | Common treatment‑related adverse events include nausea, anemia, neutropenia; interstitial lung disease occurred in 12.4% (≥ grade 3 in 4.4%) | Each chemotherapy agent carries known toxicities such as cytopenias, fatigue, and organ‑specific adverse events | Toxicity may limit use in patients with poor performance status |
| Important limitations | Safety signals require careful monitoring, including potential ILD and cytopenias; benefit compared only to single‑agent chemotherapy | Historical agents offer modest benefit with significant toxicity and limited durability | No consensus on optimal agent; efficacy often short lived, and tolerability can be challenging |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Until disease progression or unacceptable side effects
Participants receive either Ifinatamab Deruxtecan through intravenous infusion every 3 weeks or one of the standard treatments chosen by their doctor until disease progression or other stopping reasons occur.
Visits every 3 weeks
Duration - Up to 3.7 years
Participants are monitored for overall survival, tumor response, quality of life, and safety for up to approximately 3.7 years after starting treatment.
Regular scheduled visits
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Taofeek K Owonikoko, Lauren Byers, Ying Cheng...
https://pubmed.ncbi.nlm.nih.gov/41055143/Daiichi Sankyo
Lead Sponsor
Merck Sharp & Dohme LLC
Collaborating Sponsor